This slide show highlights some of the top news of 2016 on hematologic malignancies, including FDA approvals for myeloma, lymphoma, and leukemia, and studies on transplantation, risk of recurrence in AML patients, and more.
This article describes the clinical data that led to approval of these B-cell receptor inhibitors for the treatment of CLL, and highlights newer agents in clinical development that target the same kinases as the currently available therapies.
Several critical issues need to be addressed during the next several years if we are to reach the true potential of new agents like ibrutinib, idelalisib, venetoclax, ofatumumab, and obinutuzumab—which conceivably could ultimately cure CLL.
Ultimately, the management goal is not for patients with relapsed/refractory disease to live with chronic Hodgkin lymphoma while receiving immune checkpoint blockade therapy, but rather to cure more patients with first- or second-line therapy.
An 80-year-old man presented with a disabling pruritic rash characterized by disseminated and coalescing plaques on the trunk and proximal extremities and covering 40% of his total body surface area, without peripheral lymphadenopathy.